ROCHE HLDG DR (ROG.VX)
-VTX 250.40 
8.10(3.13%) 9:47AM EDT
| Prev Close: | 258.50 |
|---|
| Open: | 253.30 |
|---|
| Bid: | 250.40 |
|---|
| Ask: | 250.50 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 249.30 - 253.90 |
|---|
| 52wk Range: | 138.30 - 258.60 |
|---|
| Volume: | 1,171,920 |
|---|
| Avg Vol (3m): | 263,497 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CHF.
Headlines
- MS Patients Choose Death Risk With Potent Drug Treatmentat Bloomberg(Thu 8:22AM EDT)
- Swiss Billionaires Buy Merck Geneva Building for Biotech Campusat Bloomberg(Wed, May 22)
- Roche presents automated lab solution at conferenceat Reuters(Wed, May 22)
- Swiss stocks - Factors to watch on May 22at Reuters(Wed, May 22)
- Roche, Sigma teamed up for failed Life Technologies bid: sourcesat Reuters(Tue, May 21)
- Roche, Sigma teamed up for failed Life Technologies bid -sourcesat Reuters(Tue, May 21)
- Swiss stocks - Factors to watch on May 21at Reuters(Tue, May 21)
- Regeneron settles all pending litigation with Roche's Genentechat Reuters(Mon, May 20)
- Pfizer halts study of lymphoma drug unlikely to help survivalat Reuters(Mon, May 20)
- Glaxo Sees Emerging Market Price Cuts Driving Drug Volume Growthat Bloomberg(Fri, May 17)
- Bristol-Myers Drug Cocktail Stymies Melanoma Tumorsat Bloomberg(Thu, May 16)
- Data show new Roche leukemia drug may improve on Rituxanat Reuters(Thu, May 16)
- DEALTALK-Novartis' Vasella exit opens door to Roche stake saleat Reuters(Thu, May 16)
- Roche Experimental Leukemia Drug Helps Shrink Tumorsat Bloomberg(Thu, May 16)
- Swiss Stocks Little Changed; Richemont Rallies on Profitat Bloomberg(Thu, May 16)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forROG.VX.